JP Morgan Chase
PYXS icon

JP Morgan Chase’s Pyxis Oncology PYXS Stock Holding History

JP Morgan Chase’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Buy
5,545
+372
+7% +$711 ﹤0.01% 6789
2026
Q1 		$6.57K Sell
5,173
-341
-6% -$514 ﹤0.01% 6839
2025
Q4 		$6.34K Buy
5,514
+1,001
+22% +$3.53K ﹤0.01% 6772
2025
Q3 		$10K Buy
4,513
+2,445
+118% +$3.52K ﹤0.01% 6640
2025
Q2 		$2.27K Sell
2,068
-26,067
-93% -$29.4K ﹤0.01% 6521
2025
Q1 		$27.6K Buy
28,135
+1,059
+4% +$1.41K ﹤0.01% 6052
2024
Q4 		$42.2K Buy
27,076
+5,099
+23% +$14.7K ﹤0.01% 6078
2024
Q3 		$80.7K Buy
21,977
+665
+3% +$2.33K ﹤0.01% 5788
2024
Q2 		$70.5K Buy
21,312
+20,812
+4,162% +$87.5K ﹤0.01% 5704
2024
Q1 		$2.13K Hold
500
– – ﹤0.01% 6572
2023
Q4 		$900 Hold
500
– – ﹤0.01% 6848
2023
Q3 		$995 Sell
500
-3,813
-88% -$8.84K ﹤0.01% 6646
2023
Q2 		$11K Sell
4,313
-720
-14% -$2.28K ﹤0.01% 6040
2023
Q1 		$20K Buy
+5,033
New +$10.1K ﹤0.01% 5976
2022
Q2 		– Sell
-4,986
Closed -$20K – 6798
2022
Q1 		$20K Sell
4,986
-6,783
-58% -$49.6K ﹤0.01% 6071
2021
Q4 		$129K Buy
+11,769
New +$135K ﹤0.01% 5572

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's PYXS Position: Q2 2026 in Review

JP Morgan Chase increased its Pyxis Oncology (PYXS) stake by 7.2% in Q2 2026, buying an estimated $711 and bringing the position to 5,545 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6789.

JP Morgan Chase first reported a position in PYXS in Q4 2021 and has held it in 16 quarters since. The position peaked at $129K in Q4 2021. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • JP Morgan Chase held 5,545 shares of Pyxis Oncology worth $15.9K as of Q2 2026.
  • JP Morgan Chase bought 372 Pyxis Oncology shares in Q2 2026, an estimated $711.
  • Pyxis Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6789 holding.
  • JP Morgan Chase first reported a position in Pyxis Oncology in Q4 2021 and has held it in 16 quarters since.
  • JP Morgan Chase's Pyxis Oncology position peaked at $129K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.